603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration

• David Jackson,
• Shelley Ackerman,
• David Dornan,
• Michael Alonso,
• Felix Hartmann,
• Cecelia Pearson,
• Joseph Gonzalez,
• Po Yi Ho,
• Samuel Kimmey,
• Andrew Luo,
• Benjamin Ackerman,
• Arthur Lee,
• Richard Laura,
• Jason Paik,
• Karla Henning,
• Steven Chapin,
• Bruce Devens,
• Sean Bendall,
• Edgar Engleman

Affiliations

David Jackson

1Bolt Biotherapeutics, Redwood City, CA, USA

Shelley Ackerman

19Bolt Biotherapeutics, Redwood City, CA, USA

David Dornan

19Bolt Biotherapeutics, Redwood City, CA, USA

Michael Alonso

19Bolt Biotherapeutics, Redwood City, CA, USA

Felix Hartmann

2Stanford University, Stanford, CA, USA

Cecelia Pearson

1Bolt Biotherapeutics, Redwood City, CA, USA

Joseph Gonzalez

1Bolt Biotherapeutics, Redwood City, CA, USA

Po Yi Ho

1Bolt Biotherapeutics, Redwood City, CA, USA

Samuel Kimmey

2Stanford University, Stanford, CA, USA

Andrew Luo

1Bolt Biotherapeutics, Redwood City, CA, USA

Benjamin Ackerman

3Johns Hopkins University, Baltimore, MD, USA

Arthur Lee

1Bolt Biotherapeutics, Redwood City, CA, USA

Richard Laura

1Bolt Biotherapeutics, Redwood City, CA, USA

Jason Paik

2Stanford University, Stanford, CA, USA

Karla Henning

1Bolt Biotherapeutics, Redwood City, CA, USA

Steven Chapin

1Bolt Biotherapeutics, Redwood City, CA, USA

Bruce Devens

1Bolt Biotherapeutics, Redwood City, CA, USA

Sean Bendall

2Stanford University, Stanford, CA, USA

Edgar Engleman

2Stanford University, Stanford, CA, USA